Result was below consensus.
Goldman have EPS of 34c in FY23 and 24c in FY24.
"the key debate with the stock is the underlying (ex-Covid) profitability". GS think management are executing well.
Not a holder but considering it.
- Forums
- ASX - By Stock
- ACL
- Ann: Second letter from Crescent Capital
ACL
australian clinical labs limited
Add to My Watchlist
1.24%
!
$2.80

Ann: Second letter from Crescent Capital, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.80 |
Change
-0.035(1.24%) |
Mkt cap ! $545.9M |
Open | High | Low | Value | Volume |
$2.83 | $2.83 | $2.78 | $408.8K | 146.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 12834 | $2.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.80 | 2239 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 81406 | 2.780 |
3 | 8274 | 2.770 |
5 | 20017 | 2.760 |
8 | 7500 | 2.750 |
2 | 13616 | 2.740 |
Price($) | Vol. | No. |
---|---|---|
2.790 | 4745 | 18 |
2.800 | 4696 | 10 |
2.810 | 6510 | 6 |
2.820 | 2626 | 2 |
2.830 | 15868 | 3 |
Last trade - 11.26am 29/07/2025 (20 minute delay) ? |
Featured News
ACL (ASX) Chart |